NYSE · MTD

Mettler-Toledo International Inc.

Healthcare · Medical - Diagnostics & Research

$1,392.32▼ 1.28% ($18.12)at close

After hours$1,393.10▲ 0.06%7:30 PM ET

52-week

$1,023.05$1,525.17

What the market price implies · Reverse DCF

To support a price of $1,392.32, this model requires Stage 1 FCFF to grow by 26.34%/yr over the next 5 years, compounded annually.

Historical FCFF grew by 8.93%/yr over the past 10 years. The required annual growth rate is 17.40 percentage points higher.

Selected forecast · Base scenario

8.93%/yr · Stage 1 default · years 1–5

Annual overrides take precedence over the Stage 1 default.

Market-implied · Other assumptions held fixed

26.34%/yr · Stage 1 · years 1–5

Stage 1 growth is solved while Stage 2 growth, terminal growth, discount inputs, and annual overrides remain fixed. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Cash-flow DCF

Price used

$1,392.32

Estimated value / share

$661.20

Base scenario

This estimate is 52.51% below the price used.

USD · TTM ending 2026-06-30

Stage 1 8.93% · Stage 2 4.91% · Discount rate 11.07%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future free cash flow, discounted to its value today.

Price timestamp: Sep 18, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 19, 2026, 9:18 AM UTC · provider

Why this method?

FCFF is positive, stable, long-lived, and the business looks mature enough that a direct FCFF DCF can use historical cash flow as the anchor.

Is FCFF positive and has it been for 3+ consecutive years? 29 consecutive positive FCFF years are available.

Is FCFF stable (not swinging >30% year to year)? The largest recent FCFF swing is 27.8%.

Do you have 5+ years of positive FCFF history? 29 consecutive positive FCFF years are available.

Is the business model structurally similar to what it should be in 10 years? Revenue growth and margin behavior look mature enough for direct FCFF compounding.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: 8.17%Revenue (TTM): 6.91%FCF (TTM): 1.9%P/FCF: 25th pct

What changed

The stock rose 8.17% over the last year. Revenue grew 6.91% over the trailing twelve months. Operating margin moved from 28.38% to 28.41%. Free cash flow grew 1.9% over the trailing twelve months.

What the market seems to be pricing

The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

Operating margin currently stands at 28.41%. A decisive move in revenue — currently up 6.91% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Mettler-Toledo International Inc. (MTD) is a global enterprise dedicated to the production and provision of precision instruments and related services.

CEOPatrick K. Kaltenbach

SectorHealthcare

IndustryMedical - Diagnostics & Research

Employees16,600

IPO dateNov 14, 1997

https://www.mt.com

Market multiples

Forward P/E—

EV/EBITDA24.93

Enterprise value$31.01B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth4.48%

Gross margin (FY2025)57.52%▼0.6ppvs FY2024

Operating margin (FY2025)27.78%▼1.3ppvs FY2024

ROEN/A

Analyst consensus

RatingHold

Target price$1,466.29▲5.31%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est $12.11 · Revenue est $1.07B

View